Platelet–Monocyte Aggregates
2002; Lippincott Williams & Wilkins; Volume: 105; Issue: 18 Linguagem: Inglês
10.1161/01.cir.0000017140.26466.f5
ISSN1524-4539
AutoresJane E. Freedman, Joseph Loscalzo,
Tópico(s)Antiplatelet Therapy and Cardiovascular Diseases
ResumoHomeCirculationVol. 105, No. 18Platelet–Monocyte Aggregates Free AccessEditorialPDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toFree AccessEditorialPDF/EPUBPlatelet–Monocyte AggregatesBridging Thrombosis and Inflammation Jane E. Freedman and Joseph Loscalzo Jane E. FreedmanJane E. Freedman From the Whitaker Cardiovascular Institute and Evans Department of Medicine, Boston University School of Medicine, Boston, Mass. and Joseph LoscalzoJoseph Loscalzo From the Whitaker Cardiovascular Institute and Evans Department of Medicine, Boston University School of Medicine, Boston, Mass. Originally published7 May 2002https://doi.org/10.1161/01.CIR.0000017140.26466.F5Circulation. 2002;105:2130–2132Thrombus formation within a coronary vessel is the precipitating event in unstable coronary syndromes. The angiographic severity of coronary stenoses may not predict sites of subsequent acute coronary events, inasmuch as rupture of atheromatous plaque with thrombosis in relatively mildly stenosed vessels may underlie many acute coronary syndromes. The intact endothelium normally prevents platelet activation, but the intimal injury associated with endothelial denudation and plaque rupture exposes subendothelial collagen and von Willebrand factor, which support prompt platelet adhesion and activation. Circulating platelets can adhere either directly to collagen or indirectly, via the binding of von Willebrand factor, to the glycoprotein Ib/IX complex. Local platelet activation promotes thrombus formation and additional platelet recruitment by supporting cell surface thrombin formation and releasing potent platelet agonists, such as adenosine 5′-diphosphate, serotonin, and thromboxane A2. The central role of platelet activation in acute coronary syndromes is supported by increased platelet-derived thromboxane and prostaglandin metabolites detected in patients with acute coronary syndromes1 and the clear clinical benefit of treatment with aspirin for prevention of acute coronary events.2See p 2166The importance of platelet-dependent thrombosis has made the platelet aggregate a common therapeutic target in acute coronary syndromes. Recently, such therapies have included the use of aspirin, thienopyridines, and direct glycoprotein IIb/IIIa inhibitors. Although the mechanism of action of these various agents differs, they all inhibit fibrinogen-dependent platelet–platelet associations (ie, platelet aggregation). However, as highlighted by the recent disappointing clinical results of trials using oral glycoprotein IIb/IIIa inhibitors,3 merely preventing the process of platelet aggregation may not always translate into clinical efficacy.Recent data suggest that patients with acute coronary syndromes have not only increased interactions between platelets (homotypic aggregates) but also increased interactions between platelets and leukocytes (heterotypic aggregates) detectable in circulating blood. These aggregates form when platelets are activated and undergo degranulation, after which they adhere to circulating leukocytes. Early work suggested that these heterotypic aggregates form in inflammatory states.4 Platelets bind via P-selectin (CD62P) expressed on the surface of activated platelets to the leukocyte receptor, P-selectin glycoprotein ligand-1 (PSGL-1).5 This initial association leads to increased expression of CD11b/CD18 (Mac-1) on leukocytes,6 which itself supports interactions with platelets, perhaps because bivalent fibrinogen links this integrin with its platelet surface counterpart glycoprotein IIb/IIIa.7,8 The importance of platelet–leukocyte aggregates in vascular disease is supported by a recent study demonstrating that the infusion of recombinant human PSGL-1 in an animal model of vascular injury reduced myocardial reperfusion injury and preserved vascular endothelial function.9In acute coronary syndromes, markers of cardiac necrosis by themselves do not provide information about plaque disruption; measures of platelet–leukocyte aggregates may be a better reflection of plaque instability and ongoing vascular thrombosis and inflammation. Platelet–leukocyte aggregates also may be a more sensitive marker of platelet activation than is surface P-selectin expression because degranulated platelets rapidly lose surface P-selectin in vivo but continue to be detected in circulation.10 This is supported by a recent study by Michelson et al,11 which demonstrates that after acute myocardial infarction, circulating monocyte–platelet aggregates are a more sensitive marker of in vivo platelet activation than is platelet surface P-selectin. In addition, a study by Ott et al12 of neutrophil activation and neutrophil–platelet adhesion demonstrated that patients with unstable angina had a significant increase in neutrophil–platelet binding compared with patients with stable angina.In this issue of Circulation, Sarma et al13 add to the growing body of information about platelet–leukocyte aggregates in atherothrombosis and acute coronary syndromes. They studied 25 patients admitted with an acute coronary syndrome and compared them with 27 subjects with noncardiac chest pain, using flow cytometry to measure platelet–leukocyte binding. Compared with the subjects with noncardiac chest pain, the patients with acute coronary syndromes had increased levels of circulating platelet–monocyte aggregates. Platelet–monocyte binding was significantly decreased by saturating concentrations of a monoclonal antibody directed against PSGL-1 and the blockade of P-selectin, suggesting that monocyte binding to platelets occurs primarily through PSGL-1 and P-selectin.The study by Sarma et al13 has several significant limitations, including the small sample size and the demographic differences between the groups. The patients who had myocardial infarctions were older and had a higher prevalence of diabetes mellitus, both of which are states in which enhanced platelet reactivity has been previously demonstrated. In addition, a higher incidence of previous myocardial infarction in patients with noncardiac chest pain makes it difficult to differentiate these subjects from those in the unstable angina group in the absence of testing for cardiac ischemia.Despite these limitations, the study by Sarma et al13 supports a recent report by Furman and colleagues,14 who examined 61 patients with acute myocardial infarction and compared them with 150 control subjects. Furman et al controlled for age and found that the number of circulating monocyte–platelet aggregates was greatest in patients with acute myocardial infarction presenting within 4 hours of symptom onset. They also made the important finding that the patients presenting with acute myocardial infarction who had a normal creatine kinase isoenzyme ratio at the time of hospital presentation (just over 50%) also had elevated levels of circulating platelet–monocyte aggregates.The binding of platelets and monocytes in acute coronary syndromes highlights the interaction between inflammation and thrombosis in cardiovascular disease. Plaque rupture promotes activation of the inflammatory response, and increased expression of tissue factor initiates extrinsic coagulation. The expression of tissue factor on both endothelial cells and monocytes is partially regulated by proinflammatory cytokines, including tumor necrosis factor and interleukin-1.15 In addition to initiating coagulation, tissue factor interacts with P-selectin, accelerating fibrin formation and deposition.15 Platelet surface P-selectin also induces the expression of tissue factor on monocytes,16 enhances monocyte cytokine expression,17 and promotes CD11b/CD18 expression.6CD40–CD40 ligand (CD40L or CD154) interactions also are known to play a role in atherosclerotic, thrombotic, and inflammatory processes.18 On endothelial cells or monocytes, the engagement of CD40 with CD40L leads to the synthesis of adhesion molecules, chemokines, and tissue factor and causes the activation of matrix metalloproteinases. CD40L also is upregulated on platelets in a fresh thrombus.18 Thus, a potential additional mechanism for binding between the platelet and monocyte in the setting of acute myocardial infarction is the CD40–CD40L, representing a unique link between thrombosis and inflammation.The study by Sarma et al13 also suggests that, in addition to the interaction via P-selectin and PSGL-1, cation-independent interactions may play a role in platelet–monocyte interactions. Incubation with a calcium chelator decreased the binding of platelets to monocytes among patients with acute myocardial infarction to a greater extent than among patients with unstable angina or noncardiac chest pain. Although intriguing, it is difficult to draw any definitive conclusions from these results because most of the platelet–monocyte binding was inhibited by the chelation, and the differences between the groups were small. External chelation does not eliminate potential contribution from pathways mediated by internal Ca2+ stores because platelets contain ≈20 nmol of Ca2+/108 cells, mostly stored in dense granules. This may be relevant because surface expression of the active conformation of glycoprotein IIb/IIIa and of CD40L has been shown to be dependent on internal Ca2+ stores.19The studies by Sarma et al13 and others11,12,14 of platelet–monocyte aggregates suggest the potential utility of this measurement in diagnosing plaque activation and acute myocardial infarction. Although the study by Furman and colleagues14 first showed that circulating platelet–monocyte aggregates are an early marker of acute myocardial infarction, as compared with creatine kinase-MB, a direct comparison with troponin levels would be necessary to establish the true diagnostic utility of this measurement. It is important to note that the ease of troponin measurements greatly exceeds the significant limitations involved in the use of flow cytometry, making routine measurement of platelet–monocyte aggregates comparatively impractical at the present time. A simpler method of measuring platelet–monocyte binding would first need to be established. Possibly more important than its use as a marker of acute myocardial infarction is the fact that platelet–monocyte aggregates represent a novel index of platelet activation. Perhaps equally important, the platelet–leukocyte heterotypic aggregate represents a potential new therapeutic target for limiting thrombotic and inflammatory responses in acute coronary syndromes.All of these observations lead to the central, yet unanswered, question: Why does platelet–leukocyte binding occur in acute coronary syndromes, and what are its pathobiological consequences (if any)? Furthermore, are these aggregates merely an epiphenomenal reflection of the inflammatory and thrombotic processes occurring in the setting of acute coronary syndromes, or do they directly contribute to the ongoing atherothrombogenesis? Do they represent an initial step in the phagocytotic clearance of "spent" platelets (thrombophagocytosis) by monocytic cells? If so, what is the consequence of this phagocytosis? Early work from one of us (J.L.) showed that thrombophagocytosis by monocytic cells leads to cholesteryl ester accumulation in monocytic cells and foam cell formation in the absence of hyperlipidemia, suggesting a unique link between thrombosis and atherogenesis.20 Future studies should be directed at understanding the role of platelet–leukocyte aggregates in vascular disease, their use as a diagnostic tool, and the possible therapeutic consequences of inhibiting their formation.The opinions expressed in this editorial are not necessarily those of the editors or of the American Heart Association.The authors thank Stephanie Tribuna and Jalna Ross for expert secretarial assistance.FootnotesCorrespondence to Jane E. Freedman, MD, Boston University School of Medicine, 715 Albany St, W507, Boston, MA 02118. E-mail [email protected] References 1 Fitzgerald DJ, Roy L, Catella F, et al. Platelet activation in unstable coronary disease. N Engl J Med. 1986; 315: 983–989.CrossrefMedlineGoogle Scholar2 Antiplatelet Trialists Collaboration. Collaborative overview of randomised trials of antiplatelet therapy: I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ. 1994; 308: 81–106.CrossrefMedlineGoogle Scholar3 Chew DP, Bhatt DL, Sapp S, et al. Increased mortality with oral platelet glycoprotein IIb/IIIa antagonists: a meta-analysis of phase III multicenter randomized trials. Circulation. 2001; 103: 201–206.CrossrefMedlineGoogle Scholar4 Arber N, Berliner S, Pras E, et al. Heterotypic leukocyte aggregation in the peripheral blood of patients with leukemia, inflammation and stress. Nouv Rev Fr Hematol. 1991; 33: 251–255.MedlineGoogle Scholar5 Rinder HM, Bonan JL, Rinder CS, et al. Dynamics of leukocyte-platelet adhesion in whole blood. Blood. 1991; 78: 1730–1737.CrossrefMedlineGoogle Scholar6 Neumann FJ, Zohlnhofer D, Fakhoury L, et al. Effect of glycoprotein IIb/IIIa receptor blockade on platelet-leukocyte interaction and surface expression of the leukocyte integrin Mac-1 in acute myocardial infarction. J Am Coll Cardiol. 1999; 34: 1420–1426.CrossrefMedlineGoogle Scholar7 Gawaz MP, Loftus JC, Bajt ML, et al. Ligand bridging mediates integrin alpha IIb beta 3 (platelet GPIIB- IIIA) dependent homotypic and heterotypic cell-cell interactions. J Clin Invest. 1991; 88: 1128–1134.CrossrefMedlineGoogle Scholar8 Simon DI, Ezratty AM, Francis SA, et al. Fibrin(ogen) is internalized and degraded by activated human monocytoid cells via Mac-1 (CD11b/CD18): a nonplasmin fibrinolytic pathway. Blood. 1993; 82: 2414–2422.CrossrefMedlineGoogle Scholar9 Hayward R, Campbell B, Shin YK, et al. Recombinant soluble P-selectin glycoprotein ligand-1 protects against myocardial ischemic reperfusion injury in cats. Cardiovasc Res. 1999; 41: 65–76.CrossrefMedlineGoogle Scholar10 Michelson AD, Barnard MR, Hechtman HB, et al. In vivo tracking of platelets: circulating degranulated platelets rapidly lose surface P-selectin but continue to circulate and function. Proc Natl Acad Sci U S A. 1996; 93: 11877–11882.CrossrefMedlineGoogle Scholar11 Michelson AD, Barnard MR, Krueger LA, et al. Circulating monocyte-platelet aggregates are a more sensitive marker of in vivo platelet activation than platelet surface P-selectin: studies in baboons, human coronary intervention, and human acute myocardial infarction. Circulation. 2001; 104: 1533–1537.CrossrefMedlineGoogle Scholar12 Ott I, Neumann FJ, Gawaz M, et al. Increased neutrophil-platelet adhesion in patients with unstable angina. Circulation. 1996; 94: 1239–1246.CrossrefMedlineGoogle Scholar13 Sarma J, Laan KA, Alam S, et al. Increased platelet binding to circulating monocytes in acute coronary syndromes. Circulation. 2002; 105: 2166–2171.LinkGoogle Scholar14 Furman MI, Barnard MR, Krueger LA, et al. Circulating monocyte-platelet aggregates are an early marker of acute myocardial infarction. J Am Coll Cardiol. 2001; 38: 1002–1006.CrossrefMedlineGoogle Scholar15 Shebuski RJ, Kilgore KS. Role of inflammatory mediators in thrombogenesis. J Pharmacol Exp Ther. 2002; 300: 729–735.CrossrefMedlineGoogle Scholar16 Celi A, Pellegrini G, Lorenzet R, et al. P-selectin induces the expression of tissue factor on monocytes. Proc Natl Acad Sci U S A. 1994; 91: 8767–8771.CrossrefMedlineGoogle Scholar17 Neumann FJ, Marx N, Gawaz M, et al. Induction of cytokine expression in leukocytes by binding of thrombin-stimulated platelets. Circulation. 1997; 95: 2387–2394.CrossrefMedlineGoogle Scholar18 Henn V, Slupsky JR, Grafe M, et al. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature. 1998; 391: 591–594.CrossrefMedlineGoogle Scholar19 Hermann A, Rauch BH, Braun M, et al. Platelet CD40 ligand (CD40L)–subcellular localization, regulation of expression, and inhibition by clopidogrel. Platelets. 2001; 12: 74–82.CrossrefMedlineGoogle Scholar20 Mendelsohn ME, Loscalzo J. Role of platelets in cholesteryl ester formation by U-937 cells. J Clin Invest. 1988; 81: 62–68.CrossrefMedlineGoogle Scholar Previous Back to top Next FiguresReferencesRelatedDetailsCited BySciaudone A, Corkrey H, Humphries F and Koupenova M (2023) Platelets and SARS-CoV-2 During COVID-19: Immunity, Thrombosis, and Beyond, Circulation Research, 132:10, (1272-1289), Online publication date: 12-May-2023. Zharkova O, Salamah M, Babak M, Rajan E, Lim L, Andrade F, Gil C, Oliani S, Moraes L and Vaiyapuri S (2023) Deletion of Annexin A1 in Mice Upregulates the Expression of Its Receptor, Fpr2/3, and Reactivity to the AnxA1 Mimetic Peptide in Platelets, International Journal of Molecular Sciences, 10.3390/ijms24043424, 24:4, (3424) Liang S, Wang Y, Ji Y, Na S, Jia X, Zhao S, Lyu H, Yuan X and Bao Y (2023) Circulating monocyte-platelet aggregates with different monocyte subsets and their association with disease severity in chronic kidney disease, The American Journal of the Medical Sciences, 10.1016/j.amjms.2023.02.003, Online publication date: 1-Feb-2023. Mayorova O, Gusliakova O, Prikhozhdenko E, Verkhovskii R and Bratashov D (2023) Magnetic Platelets as a Platform for Drug Delivery and Cell Trapping, Pharmaceutics, 10.3390/pharmaceutics15010214, 15:1, (214) L. A and HASHIM M (2022) IN VITRO ANTIPLATELET ACTIVITY OF AN ISOFLAVANONE ISOLATED FROM METHANOLIC EXTRACT OF EMBLICA OFFICINALIS FRUITS, International Journal of Pharmacy and Pharmaceutical Sciences, 10.22159/ijpps.2022v14i11.46212, (48-53) Singam N, AlAdili B, Amraotkar A, Coulter A, Singh A, Kulkarni S, Mitra R, Daham O, Smith A and DeFilippis A (2022) In-vivo platelet activation and aggregation during and after acute atherothrombotic myocardial infarction in patients with and without Type-2 diabetes mellitus treated with ticagrelor, Vascular Pharmacology, 10.1016/j.vph.2022.107000, 145, (107000), Online publication date: 1-Aug-2022. Khiabani Rad M, Vazifeh Shiran N, Mohammadi M and Hamidpour M (2021) Evaluating the effect of cinnamon and rosuvastatin, on the formation of foam cells in macrophages co-cultured with platelets, Advances in Traditional Medicine, 10.1007/s13596-020-00537-4, 22:2, (271-281), Online publication date: 1-Jun-2022. Zhang Z, Shen C, Fang M, Han Y, Long C, Liu W, Yang M, Liu M, Zhang D, Cao Q, Chen X, Fang Y, Lu Q, Hou Z, Li Y, Liu Z, Lei X, Ni H and Lai R (2022) Novel contact–kinin inhibitor sylvestin targets thromboinflammation and ameliorates ischemic stroke, Cellular and Molecular Life Sciences, 10.1007/s00018-022-04257-7, 79:5, Online publication date: 1-May-2022. Oussoren F, Poulsen L, Kardux J, Schermer T, Bruintjes T and van Leeuwen R (2022) Cerebral Small Vessel Disease in Elderly Patients With Vestibular Neuritis, Frontiers in Neurology, 10.3389/fneur.2022.818533, 13 Begum F, Me H and Christov M (2022) The Role of Zinc in Cardiovascular Disease, Cardiology in Review, 10.1097/CRD.0000000000000382, 30:2, (100-108), Online publication date: 1-Mar-2022. Koupenova M, Livada A and Morrell C (2022) Platelet and Megakaryocyte Roles in Innate and Adaptive Immunity, Circulation Research, 130:2, (288-308), Online publication date: 21-Jan-2022. Lee Y and Rhee M (2022) Atherosclerosis Recent Advancements in Microbial Diversity, 10.1016/B978-0-12-822368-0.00012-8, (265-275), . Hou D, Wang C, Ye X, Zhong P and Wu D (2021) Persistent inflammation worsens short-term outcomes in massive stroke patients, BMC Neurology, 10.1186/s12883-021-02097-9, 21:1, Online publication date: 1-Dec-2021. Xiao X, Huang S, Chen S, Wang Y, Sun Q, Xu X and Li Y (2021) Mechanisms of cytokine release syndrome and neurotoxicity of CAR T-cell therapy and associated prevention and management strategies, Journal of Experimental & Clinical Cancer Research, 10.1186/s13046-021-02148-6, 40:1 Gao Y, Zhang J, Chen H, Wang Z, Hou J and Wang L (2021) Dimethylamine enhances platelet hyperactivity in chronic kidney disease model, Journal of Bioenergetics and Biomembranes, 10.1007/s10863-021-09913-4, 53:5, (585-595), Online publication date: 1-Oct-2021. Sarıcam G (2020) Relationship between migraine headache and hematological parameters, Acta Neurologica Belgica, 10.1007/s13760-020-01362-x, 121:4, (899-905), Online publication date: 1-Aug-2021. OCAK Ö and ŞAHİN E (2021) Migren Baş Ağrısının Nötrofil-Lenfosit Oranı, Platelet Lenfosit Oranı ve Eritrosit Dağılım Genişliği ile İlişkisi, Mustafa Kemal Üniversitesi Tıp Dergisi, 10.17944/mkutfd.913390 Stojkovic S, Wadowski P, Haider P, Weikert C, Pultar J, Lee S, Eichelberger B, Hengstenberg C, Wojta J, Panzer S, Demyanets S and Gremmel T (2021) Circulating MicroRNAs and Monocyte–Platelet Aggregate Formation in Acute Coronary Syndrome, Thrombosis and Haemostasis, 10.1055/s-0040-1722226, 121:07, (913-922), Online publication date: 1-Jul-2021. Bosco O, Vizio B, Gruden G, Schiavello M, Lorenzati B, Cavallo-Perin P, Russo I, Montrucchio G and Lupia E (2021) Thrombopoietin Contributes to Enhanced Platelet Activation in Patients with Type 1 Diabetes Mellitus, International Journal of Molecular Sciences, 10.3390/ijms22137032, 22:13, (7032) Cai L, Zeng H, Tan X, Wu X, Qian C and Chen G (2021) The Role of the Blood Neutrophil-to-Lymphocyte Ratio in Aneurysmal Subarachnoid Hemorrhage, Frontiers in Neurology, 10.3389/fneur.2021.671098, 12 Pavlov O, Chepanov S, Selutin A, Zainulina M, Eremeeva D and Selkov S (2021) Flow cytofluorimetric detection and immunophenotyping of platelet-monocyte complexes in peripheral blood, Medical Immunology (Russia), 10.15789/1563-0625-FCD-2124, 23:2, (401-410) Fu G, Deng M, Neal M, Billiar T and Scott M (2020) Platelet–Monocyte Aggregates: Understanding Mechanisms and Functions in Sepsis, Shock, 10.1097/SHK.0000000000001619, 55:2, (156-166), Online publication date: 1-Feb-2021. Kheiabani Rad M, Mohammadi M, Vazifeh Shiran N and Hamidpour M (2021) Inhibitory effect of Cinnamon on prevention of foam cell formation in platelet and monocytes co-culture, Koomesh journal, 10.29252/koomesh.23.1.139, 23:1, (139-145) Vinci R, Pedicino D, D'Aiello A, Ciampi P, Ponzo M, Bonanni A, Russo G, Montone R, Massetti M, Crea F and Liuzzo G (2021) Platelet hyaluronidase 2 enrichment in acute coronary syndromes: a conceivable role in monocyte-platelet aggregate formation, Journal of Enzyme Inhibition and Medicinal Chemistry, 10.1080/14756366.2021.1900159, 36:1, (785-789), Online publication date: 1-Jan-2021. Singh A, Coulter A, Trainor P, Singam N, Aladili B, Amraotkar A, Owolabi U and DeFilippis A (2020) Flow cytometric evaluation of platelet–leukocyte conjugate stability over time: methodological implications of sample handling and processing, Journal of Thrombosis and Thrombolysis, 10.1007/s11239-020-02186-5, 51:1, (120-128), Online publication date: 1-Jan-2021. McFadyen J, Stevens H and Peter K (2020) The Emerging Threat of (Micro)Thrombosis in COVID-19 and Its Therapeutic Implications, Circulation Research, 127:4, (571-587), Online publication date: 31-Jul-2020. Han P, Hanlon D, Arshad N, Lee J, Tatsuno K, Yurter A, Robinson E, Filler R, Sobolev O, Cote C, Rivera-Molina F, Toomre D, Fahmy T and Edelson R (2020) Platelet P-selectin initiates cross-presentation and dendritic cell differentiation in blood monocytes, Science Advances, 10.1126/sciadv.aaz1580, 6:11, Online publication date: 13-Mar-2020. Gasecka A, Nieuwland R, Budnik M, Dignat‐George F, Eyileten C, Harrison P, Lacroix R, Leroyer A, Opolski G, Pluta K, van der Pol E, Postuła M, Siljander P, Siller‐Matula J and Filipiak K (2020) Ticagrelor attenuates the increase of extracellular vesicle concentrations in plasma after acute myocardial infarction compared to clopidogrel, Journal of Thrombosis and Haemostasis, 10.1111/jth.14689, 18:3, (609-623), Online publication date: 1-Mar-2020. Hermawati I and Assegaf M (2020) Association between White Blood Cell to Mean Platelet Volume Ratio (WMR) with Troponin for Refractory Angina Prediction in NSTE-ACS patients, IOP Conference Series: Earth and Environmental Science, 10.1088/1755-1315/441/1/012176, 441:1, (012176), Online publication date: 1-Feb-2020. Barrett T, Schlegel M, Zhou F, Gorenchtein M, Bolstorff J, Moore K, Fisher E and Berger J (2019) Platelet regulation of myeloid suppressor of cytokine signaling 3 accelerates atherosclerosis, Science Translational Medicine, 10.1126/scitranslmed.aax0481, 11:517, Online publication date: 6-Nov-2019. Lin H, Tsai W, Lin J, Chang W, Huang C, Wang H, Kung C, Su C, Su Y, Lin W, Cheng B, Lu C and Tsai N (2019) Adjunctive statin therapy reduces intracranial hemorrhage and 1-year mortality in patients with atrial fibrillation after acute ischemic stroke: A population-based epidemiological study from Taiwan, Journal of Clinical Neuroscience, 10.1016/j.jocn.2019.07.045, 69, (224-229), Online publication date: 1-Nov-2019. Jansson P and Kay B (2019) Aldehydes identified in commercially available ω-3 supplements via 1 H NMR spectroscopy, Nutrition, 10.1016/j.nut.2018.10.004, 60, (74-79), Online publication date: 1-Apr-2019. Fu W, Wang J, Jiang H and Hu X (2019) Myocardial infarction induces bone marrow megakaryocyte proliferation, maturation and platelet production, Biochemical and Biophysical Research Communications, 10.1016/j.bbrc.2019.01.129, 510:3, (456-461), Online publication date: 1-Mar-2019. Allen N, Barrett T, Guo Y, Nardi M, Ramkhelawon B, Rockman C, Hochman J and Berger J (2019) Circulating monocyte-platelet aggregates are a robust marker of platelet activity in cardiovascular disease, Atherosclerosis, 10.1016/j.atherosclerosis.2018.12.029, 282, (11-18), Online publication date: 1-Mar-2019. Sotiri I, Robichaud M, Lee D, Braune S, Gorbet M, Ratner B, Brash J, Latour R and Reviakine I (2019) BloodSurf 2017: News from the blood-biomaterial frontier, Acta Biomaterialia, 10.1016/j.actbio.2019.01.032, 87, (55-60), Online publication date: 1-Mar-2019. Shushan S, Shemesh S, Ungar O, Cavel O, Handzel O, Tamir S and Oron Y (2019) Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio among Patients with Vestibular Neuritis, ORL, 10.1159/000502152, 81:5-6, (304-308), . Han W, Wang D, Wu Y, Fan Z, Guo X and Guan Q (2018) Correlation between vestibular neuritis and cerebrovascular risk factors, American Journal of Otolaryngology, 10.1016/j.amjoto.2018.08.006, 39:6, (751-753), Online publication date: 1-Nov-2018. Veselkina O, Petrishchev N, Vasina L, Borovitov M, Selyutin A, Chepanov S and Sel'kov S (2018) Effects of Nothrombel on Thrombin-Induced Formation of Thrombocyte-Leukocyte Complexes, Neuroscience and Behavioral Physiology, 10.1007/s11055-018-0636-y, 48:7, (830-834), Online publication date: 1-Sep-2018. Haynes A, Linden M, Robey E, Naylor L, Ainslie P, Cox K, Lautenschlager N and Green D (2018) Beneficial impacts of regular exercise on platelet function in sedentary older adults: evidence from a randomized 6-mo walking trial, Journal of Applied Physiology, 10.1152/japplphysiol.00079.2018, 125:2, (401-408), Online publication date: 1-Aug-2018. Alshbool F, Karim Z, Espinosa E, Lin O and Khasawneh F (2018) Investigation of a Thromboxane A2 Receptor–Based Vaccine for Managing Thrombogenesis, Journal of the American Heart Association, 7:13, Online publication date: 3-Jul-2018. Zamora C, Canto E, Nieto J, Garcia-Planella E, Gordillo J, Ortiz M, Suarez-Calvet X, Perea L, Julia G, Juarez C and Vidal S (2018) Inverse Association Between Circulating Monocyte-Platelet Complexes and Inflammation in Ulcerative Colitis Patients, Inflammatory Bowel Diseases, 10.1093/ibd/izx106, 24:4, (818-828), Online publication date: 19-Mar-2018. Pal'chun V, Makoeva A and Guseva A (2018) Dizziness and vertigo associated with vestibular neuronitis: the approaches to the diagnostics and treatment, Vestnik otorinolaringologii, 10.17116/otorino20188334, 83:3, (4), . Shammas N (2018) Thrombotic Lesions in the Lower Extremity Peripheral Arteries Cardiovascular Thrombus, 10.1016/B978-0-12-812615-8.00032-6, (459-467), . Thompson K, Hosking H, Pederick W, Singh I and Santhakumar A (2017) The effect of anthocyanin supplementation in modulating platelet function in sedentary population: a randomised, double-blind, placebo-controlled, cross-over trial, British Journal of Nutrition, 10.1017/S0007114517002124, 118:5, (368-374), Online publication date: 14-Sep-2017. Oron Y, Shemesh S, Shushan S, Cinamon U, Goldfarb A, Dabby R and Ovnat Tamir S (2017) Cardiovascular Risk Factors Among Patients With Vestibular Neuritis, Annals of Otology, Rhinology & Laryngology, 10.1177/0003489417718846, 126:8, (597-601), Online publication date: 1-Aug-2017. Hegemann S and Wenzel A (2017) Diagnosis and Treatment of Vestibular Neuritis/Neuronitis or Peripheral Vestibulopathy (PVP)? Open Questions and Possible Answers, Otology & Neurotology, 10.1097/MAO.0000000000001396, 38:5, (626-631), Online publication date: 1-Jun-2017. Chung J, Lee S, Park C, Jeong J and Shin J (2017) Clinical Significance of Arterial Stiffness and Metabolic Syndrome Scores in Vestibular Neuritis, Otology & Neurotology, 10.1097/MAO.0000000000001352, 38:5, (737-741), Online publication date: 1-Jun-2017. Yang K, Du C, Wang X, Li F, Xu Y, Wang S, Chen S, Chen F, Shen M, Chen M, Hu M, He T, Su Y, Wang J and Zhao J (2017) Indoxyl sulfate induces platelet hyperactivity and contributes to chronic kidney disease–associated thrombosis in mice, Blood, 10.1182/blood-2016-10-744060, 129:19, (2667-2679), Online publication date: 11-May-2017. Manne B, Xiang S and Rondina M (2016) Platelet secretion in inflammatory and infectious diseases, Platelets, 10.1080/09537104.2016.1240766, 28:2, (1
Referência(s)